Overview

Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer

Status:
Recruiting
Trial end date:
2023-05-15
Target enrollment:
Participant gender:
Summary
Patients with recurrent or metastatic cervical cancer，and will be treated with GLS-010.
Phase:
Phase 2
Details
Lead Sponsor:
Guangzhou Gloria Biosciences Co., Ltd.
Treatments:
Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoglobulins